Table 1 Baseline characteristics
From: Wearable defibrillator use in heart failure (WIF): results of a prospective registry
Baseline characteristics | Total (n=82) |
|---|---|
Sex: Males (%) | 59 (72%) |
Age: Mean (SD) | 61.0 (11.1) |
Range | 37-83 |
Baseline EF (SD) | 23.9% (9.4%) |
Range | 7.5%-65% |
Baseline NYHA class (%) | n=74 |
Class I | 11 (14.9%) |
Class II | 20 (27.0%) |
Class III | 40 (54.1%) |
Class IV | 3 (4.1%) |
Prior MI (n=78) | 17 (21.8%) |
Prior PCI (n=80) | 10 (12.5%) |
Prior CABG (n=81) | 17 (21.0%) |
Prior sustained VT (n=82) | 4 (4.9%) |
Prior VF (n=79) | 1 (1.3%) |
HTN (n=81) | 55 (67.9%) |
Diabetes (n=81) | 36 (44.4%) |
Smoking (n=81) | 45 (55.6%) |
BMI | n=69 |
<18.5 | 2 (2.9%) |
18.5-24.9 | 20 (29.0%) |
25–29.9 | 18 (26.1%) |
>30 | 29 (42.0%) |
ECG | n=81 |
Atrial Fibrillation | 8 (9.9%) |
Bradycardia | 3 (3.7%) |
Sinus rhythm with 1st deg AV block | 2 (2.5%) |
Left bundle branch block | 3 (3.7%) |
Right bundle branch block | 2 (2.5%) |
Sinus tachycardia | 12 (14.8%) |
Multiple PVCs | 4 (4.9%) |
Device History | |
Active pacemaker | 2 (2.4%) |
Past/inactive pacemaker | 2 (2.4%) |
Prior/inactive ICD | 4 (4.9%) |
Medications | |
Beta Blockers | 78 (95.1%) |
ACE Inhibitors | 63 (76.8%) |
Angiotensin II Receptor Blockers | 16 (19.5%) |
Anti-arrhythmics | 7 (8.5%) |